

(A NON-PROFIT CORPORATION)

AUDITED CONSOLIDATED FINANCIAL STATEMENTS AND SUPPLEMENTARY SCHEDULES

FOR THE YEAR ENDED DECEMBER 31, 2022 (WITH COMPARATIVE TOTALS FOR THE YEAR ENDED December 31, 2021)

with

INDEPENDENT AUDITORS' REPORT THEREON



(A NON-PROFIT CORPORATION)

| | INDEX |
|--|-------------|
| | Page |
| Independent Auditors' Report | 1 - 3 |
| Consolidated Statements of Financial Position | 4 |
| Consolidated Statements of Activities | 5 |
| Consolidated Statements of Functional Expenses | 6 |
| Consolidated Statements of Cash Flows | 7 |
| Notes to Consolidated Financial Statements | 8 - 17 |
| Supplementary Schedules: | |
| Consolidating Schedule of Financial Position | 18 |
| Consolidating Schedule of Activities | 19 |
| Consolidating Schedule of Functional Expenses | 20 |



Independent Auditors' Report

To the Board of Directors Open Medicine Foundation

Opinion

We have audited the consolidated financial statements of Open Medicine Foundation (the "Organization," a non-profit corporation), which comprise the consolidated statements of financial position as of December 31, 2022, and the related consolidated statements of activities, functional expenses, and cash flows for the year then ended, and the related notes to the consolidated financial statements.

In our opinion, the accompanying consolidated financial statements present fairly, in all material respects, the financial position of the Organization as of December 31, 2022, and the change in their net assets and their cash flows for the year then ended in accordance with accounting principles generally accepted in the United States of America.

Basis for Opinion

We conducted our audit in accordance with auditing standards generally accepted in the United States of America ("GAAS"). Our responsibilities under those standards are further described in the Auditors' Responsibilities for the Audit of the Financial Statements section of our report. We are required to be independent of the Organization, and to meet our other ethical responsibilities, in accordance with the relevant ethical requirements relating to our audit. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Responsibilities of Management for the Financial Statements

Management is responsible for the preparation and fair presentation of the consolidated financial statements in accordance with accounting principles generally accepted in the United States of America, and for the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of consolidated financial statements that are free from material misstatement, whether due to fraud or error. In preparing the consolidated financial statements, management is required to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Organization's ability to continue as a going concern for one year after the date that the consolidated financial statements are issued.

P (310) 540-4118 F (310) 543-2051



Auditors' Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the consolidated financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditors' report that includes our opinion. Reasonable assurance is a high level of assurance but is not absolute assurance and therefore is not a guarantee that an audit conducted in accordance with GAAS will always detect a material misstatement when it exists.

The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Misstatements are considered material if there is a substantial likelihood that, individually or in the aggregate, they would influence the judgment made by a reasonable user based on the consolidated financial statements.

In performing an audit in accordance with GAAS, we:

- Exercise professional judgment and maintain professional skepticism throughout the audit.
- Identify and assess the risks of material misstatement of the consolidated financial statements, whether due to fraud or error, and design and perform audit procedures responsive to those risks. Such procedures include examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Organization's internal control. Accordingly, no such opinion is expressed.
- Evaluate the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluate the overall presentation of the consolidated financial statements.
- Conclude whether, in our judgment, there are conditions or events, considered in the aggregate, that raise substantial doubt about the Organization's ability to continue as a going concern for a reasonable period of time.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit, significant audit findings, and certain internal control–related matters that we identified during the audit.



We did not audit the financial statements of Open Medicine Foundation Canada and Open Medicine Foundation Australia, related entities, which statements reflect total assets constituting 13% and 4%, respectively, of consolidated total assets at December 31, 2022, and total revenues and support constituting 21% and 3%, respectively, of consolidated total revenues and support for the year then ended. Those statements were audited by other auditors in accordance with Canadian and Australian generally accepted auditing standards, respectively, whose report has been furnished to us, and our opinion, insofar as it relates to the amounts included for Open Medicine Foundation Canada and Open Medicine Foundation Australia, is based solely on the report of, and additional audit procedures to meet the relevant requirements of auditing standards generally accepted in the United States of America performed by, the other auditors.

Supplementary Information

Our audit was conducted for the purpose of forming an opinion on the consolidated financial statements as a whole. The supplementary consolidating information is presented for purposes of additional analysis and is not a required part of the consolidated financial statements. Such information is the responsibility of management and was derived from and relates directly to the underlying accounting and other records used to prepare the consolidated financial statements. The information has been subjected to the auditing procedures applied in the audit of the consolidated financial statements and certain additional procedures, including comparing and reconciling such information directly to the underlying accounting and other records used to prepare the consolidated financial statements themselves, and other additional procedures in accordance with auditing standards generally accepted in the United States of America. In our opinion, the information is fairly stated in all material respects in relation to the consolidated financial statements as a whole.

Report on Summarized Comparative Information

We have previously audited the Organization's December 31, 2021 financial statements, and we expressed an unmodified audit opinion on those audited financial statements in our report dated April 26, 2022. In our opinion, the summarized comparative information presented herein as of and for the year ended December 31, 2021 is consistent, in all material respects, with the audited consolidated financial statements from which it has been derived.

UM, LL

Torrance, California April 18, 2023

(A NON-PROFIT CORPORATION)

CONSOLIDATED STATEMENTS OF FINANCIAL POSITION DECEMBER 31, 2022 (WITH COMPARATIVE TOTALS FOR DECEMBER 31, 2021)

| | | 2022 | 2021 | | |
|---------------------------------------|------|------------|------|------------|--|
| ASSETS | | | | | |
| CURRENT ASSETS | | | | | |
| Cash and cash equivalents | \$ | 7,683,163 | \$ | 10,620,133 | |
| Investments | | 1,492,250 | | - | |
| Contributions receivable | | 1,332,466 | | - | |
| Other receivables | | 2,591 | | 929 | |
| | \$ | 10,510,470 | \$ | 10,621,062 | |
| LIABILITIES AND NET ASS | SETS | | | | |
| CURRENT LIABILITIES | | | | | |
| Accounts payable and accrued expenses | \$ | 45,873 | \$ | 60,786 | |
| Grants payable | | 3,778,697 | | 986,338 | |
| | | 3,824,570 | | 1,047,124 | |
| NET ASSETS | | | | | |
| Without donor restrictions | | 2,938,141 | | 5,909,879 | |
| With donor restrictions | | 3,747,759 | | 3,664,059 | |
| | | 6,685,900 | | 9,573,938 | |
| | \$ | 10,510,470 | \$ | 10,621,062 | |

CONSOLIDATED STATEMENTS OF ACTIVITIES DECEMBER 31, 2022 (WITH COMPARATIVE TOTALS FOR DECEMBER 31, 2021)

| | | 2022 | | | | | | | | |
|--|----------------------------------|----------------------------|--------------|---------------------|--|--|--|--|--|--|
| | Without Donor Restrictions | With Donor Restrictions | Total | Summarized Total | | | | | | |
| | Kesti ictions | Restrictions | 10181 | 10141 | | | | | | |
| REVENUE AND SUPPORT | | | | | | | | | | |
| Contributions | \$ 1,790,140 | \$ 391,720 | \$ 2,181,860 | \$ 4,799,527 | | | | | | |
| Grants | 421,713 | 2,613,951 | 3,035,664 | 2,858,866 | | | | | | |
| Other income | 1,675 | - | 1,675 | 26,360 | | | | | | |
| Interest and dividend income | 19,268 | - | 19,268 | 1,369 | | | | | | |
| Loss on investments | (18,514) | - | (18,514) | - | | | | | | |
| CARES Act PPP loan payable forgiveness | - | - | - | 196,775 | | | | | | |
| Net assets released from restrictions | 2,921,971 | (2,921,971) | - | - | | | | | | |
| | 5,136,253 | 83,700 | 5,219,953 | 7,882,897 | | | | | | |
| FUNCTIONAL EXPENSES | | | | | | | | | | |
| Program services | 7,217,815 | - | 7,217,815 | 4,252,049 | | | | | | |
| Supporting services | 296,527 | - | 296,527 | 281,218 | | | | | | |
| Fundraising | 465,958 | - | 465,958 | 467,647 | | | | | | |
| | 7,980,300 | | 7,980,300 | 5,000,914 | | | | | | |
| OTHER ITEMS | | | | | | | | | | |
| Foreign currency translation loss | (127,691) | | (127,691) | (2,313) | | | | | | |
| CHANGE IN NET ASSETS | (2,971,738) | 83,700 | (2,888,038) | 2,879,670 | | | | | | |
| NET ASSETS, beginning of year | 5,909,879 | 3,664,059 | 9,573,938 | 6,694,268 | | | | | | |
| NET ASSETS, end of year | \$ 2,938,141 | \$ 3,747,759 | \$ 6,685,900 | \$ 9,573,938 | | | | | | |

CONSOLIDATED STATEMENTS OF FUNCTIONAL EXPENSES YEAR ENDED DECEMBER 31, 2022 (WITH COMPARATIVE TOTALS FOR DECEMBER 31, 2021)

| | | 2021 | | | |
|-------------------------------------|----------------------|------------------------|----------------------|----------------------|----------------------|
| | Program Services | Supporting Services | Fundraising | Total | Summarized Total |
| Salaries and wages Payroll taxes | \$ 362,799 22,244 | \$ 155,528 9,535 | \$ 313,829 19,242 | \$ 832,156 51,021 | \$ 742,813 52,503 |
| Employee benefits | 12,121 | 5,196 | 19,242 | 27,802 | 43,268 |
| Total personnel expenses | 397,164 | 170,259 | 343,556 | 910,979 | 838,584 |
| Program and research grants | 6,571,363 | - | - | 6,571,363 | 3,740,206 |
| Professional services | 185,731 | 43,575 | 2,742 | 232,048 | 223,659 |
| Merchant fees | - | - | 65,078 | 65,078 | 46,665 |
| Marketing and | | | | | |
| communications | 28,883 | - | 28,882 | 57,765 | 27,809 |
| Information technology | 15,736 | 10,721 | 25,700 | 52,157 | 69,078 |
| Travel, meetings and | | | | | |
| conferences | - | 48,420 | - | 48,420 | 9,897 |
| Website | 18,938 | - | - | 18,938 | 5,312 |
| General administration | - | 11,580 | - | 11,580 | 9,817 |
| Insurance | - | 11,347 | - | 11,347 | 12,944 |
| Taxes and licenses | - | 625 | - | 625 | 2,680 |
| Fundraising | | | | | 14,263 |
| | \$7,217,815 | \$ 296,527 | \$ 465,958 | \$7,980,300 | \$ 5,000,914 |

(A NON-PROFIT CORPORATION)

CONSOLIDATED STATEMENTS OF CASH FLOWS YEAR ENDED DECEMBER 31, 2022 (WITH COMPARATIVE TOTALS FOR DECEMBER 31, 2021)

| | | 2022 | | 2021 |
|--|----|-------------------------|----|------------|
| CASH FLOWS FROM OPERATING ACTIVITIES Change in net assets | \$ | (2,888,038) | ¢ | 2,879,670 |
| Adjustments to reconcile change in net assets to net cash from operating activities: | ψ | (2,000,030) | Ψ | 2,079,070 |
| Loss on investments | | 18,514 | | - |
| CARES Act PPP loan payable forgiveness Changes in operating assets and liabilities: | | - | | (196,775) |
| Contributions and other receivables | | (1,334,128) | | 569,395 |
| Accounts payable and accrued expenses | | (14,913) | | (14,260) |
| Grants payable | | 2,792,359 | | (581,417) |
| Net cash flows from operating activities | | (1,426,206) | | 2,656,613 |
| CASH FLOWS FROM INVESTING ACTIVITIES Purchase of investments | | (1.500.000) | | |
| Interest and dividends reinvested | | (1,500,000) (10,764) | | - |
| | | | | |
| Net cash flows from investing activities | | (1,510,764) | | - |
| CASH FLOWS FROM FINANCING ACTIVITIES | | | | |
| Proceeds from CARES Act forgivable PPP loan | | - | | 106,400 |
| Net cash flows from financing activities | | - | | 106,400 |
| Net change cash and cash equivalents | | (2,936,970) | | 2,763,013 |
| Cash and cash equivalents, beginning of year | | 10,620,133 | | 7,857,120 |
| Cash and cash equivalents, end of year | \$ | 7,683,163 | \$ | 10,620,133 |

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS DECEMBER 31, 2022

NOTE 1 - ORGANIZATION

Open Medicine Foundation, Inc. (the "Foundation," the "Organization," a non-profit corporation) was founded in 2012 to fund collaborative medical research and medical education for multi system chronic complex diseases. Its four primary goals are to: 1) frame clear disease mechanisms and models; 2) to find effective treatments and diagnostic markers; 3) increase accurate diagnoses; and 4) ensure access to quality care.

The Organization supports research through six collaborative research centers globally and medical education through one medical education resource center (in partnership with the Bateman Horne Center), and by bringing together a community of "thought leaders," patients, clinicians and researchers for targeted initiatives. Open Medicine Foundation is currently focused on researching Myalgic Encephalomyelitis/ Chronic Fatigue Syndrome ("ME/CFS"), post-infectious Lyme disease, and Long COVID, in hopes of also revealing answers to other multi system chronic complex diseases that share similar symptoms.

The Organization raises funds through three separate entities: Open Medicine Foundation Inc. (OMF), Open Medicine Foundation Canada (OMFCA), and Open Medicine Foundation Australia Limited (OMFAL). All donations received are from private donors—individuals, families, other foundations, etc. OMF receives donations from donors globally and is able to fund research via any of the six collaborative research centers. OMF Canada receives donations form Canadian donors, and is able to fund research at institutions of "qualified donees." OMF Australia Limited receives donations from Australia resident donors and a handful of US donors. Any funds received through OMFAL remain in Australia to fund the Melbourne Collaborative Research Center.

Each entity is overseen by a Foundation Board and its research is also driven by its Scientific Advisory Board. OMF is also the sole member of the other two entities. OMF provides all back office support and administration to the other two entities. OMF and OMFAL have a formal Services Agreement in place, and the same is being drafted for OMF and OMFCA.

Principles of Consolidation - The accompanying consolidated financial statements include the accounts of the Foundation, the Canadian Corporation and the Australian Limited Entity (collectively, the "Organization"). Both the Canadian Corporation and the Australian Limited Entity share two board members and the dependency on the Foundation for its back office and administrative function. The Australian Limited Entity is consolidated on a basis of ownership as it is a 100% subsidiary of the Foundation. Inter-company balances and transactions, if any, have been eliminated in consolidation.

Funding - The Organization is funded primarily through foundation grants, corporate grants, and private individual donations.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS DECEMBER 31, 2022

NOTE 1 - ORGANIZATION, Continued

Liquidity and availability of resources - The following reflects the Organization's financial assets as December 31, 2022, reduced by amounts not available for general use within one year of the balance sheet date:

| Cash and cash equivalents | \$ 7,683,163 |
|---|--------------|
| Investments | 1,492,250 |
| Contributions receivable | 1,332,466 |
| Other receivables | 2,591 |
| Total financial assets | 10,510,470 |
| Net assets with donor restrictions | (3,747,759) |
| Financial assets available to meet cash needs for | |
| general expenditures within one year | \$ 6,762,711 |

This is near the Organization's goal to maintain financial assets on hand to meet at least one year of normal operating expenses which, on average, totals approximately \$665,000 per month given full programmatic expenditures. The Organization plans to spend the available funds for the intended purpose of its philanthropic mission as soon as able.

COVID-19 impact - During March 2020, the World Health Organization declared the spread of Coronavirus disease, or COVID-19, a worldwide pandemic. The COVID-19 pandemic has caused significant effects on global markets, supply chains, businesses and communities. Management believes that the pandemic slowed the Organization's ability to carry out its mission. However, management believes that the Organization has adapted its channels to reach the donors and the research community amidst the restrictions imposed by the federal and state governments. It is possible that COVID-19 could continue to negatively impact the Organization's 2023 operations. The duration of these uncertainties and the ultimate financial effects cannot be reasonably estimated at this time.

CARES Act forgivable loan payable - Management believes the Organization is taking appropriate action to mitigate the potential negative financial impact of COVID-19, including participation in the Paycheck Protection Program (the "PPP Loan") administered by the U.S. Small Business Administration ("SBA"). Through the program, the Organization secured low-interest loans of \$90,375 and \$106,400 in 2020 and 2021, respectively.

During 2021, both PPP Loans, with an aggregate balance of \$196,775, were forgiven based on the Organization's use of the proceeds for its payroll costs and other expenses in accordance with the requirements of the CARES Act. This aggregate amount was recognized as CARES Act PPP loan payable forgiveness support in the accompanying Statement of Activities as of December 31, 2021.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS DECEMBER 31, 2022

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of presentation - The accompanying consolidated financial statements have been prepared on the accrual basis of accounting in accordance with accounting principles generally accepted in the United States of America. Net assets and revenues, expenses, gains, and losses are classified based on the existence or absence of donor-imposed restrictions. Accordingly, net assets of the Organization and changes therein are classified and reported as follows:

Net assets without donor restrictions - Net assets available for use in general operations and not subject to donor or certain grantor restrictions.

Net assets with donor restrictions - Net assets with donor restrictions are assets subject to donor or grantor-imposed restrictions, some of which are temporary in nature, such as those that will be met by the passage of time or other events specified by the donor, while others are perpetual in nature, where the donor stipulates the resources be maintained in perpetuity.

Revenues are reported as increases in net assets without donor restrictions unless use of the related assets is limited by donor-imposed restrictions. Expenses are reported as decreases in net assets without donor restrictions. Expirations of net assets with donor restrictions are reported as reclassifications between the applicable classes of net assets.

Estimates - The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.

Contributions and pledges - Contributions and pledges are recognized at fair value when the donor makes an unconditional transfer of cash or other assets, as well as unconditional promise to give to the Organization. Contributions and pledges that are restricted by the donor are recognized when the conditions on which they depend have been substantially met and reported as increases in net assets without donor restrictions if the restrictions expire in the fiscal year in which the contributions are recognized. All other donor-restricted contributions are reported as increases in net assets with donor restrictions depending on the nature of the restrictions. When a restriction expires, net assets with donor restrictions are reclassified to net assets without donor restrictions.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS DECEMBER 31, 2022

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Continued

Contributions of services are recognized in the consolidated financial statements (as in-kind revenue and a corresponding in-kind expense) if the services enhance or create non-financial assets or require specialized skills and are provided by individuals possessing those skills and would typically need to be purchased if not provided by donation. During the year ended December 31, 2022, several volunteers who perform services for the Organization have contributed significant amounts of time to the Organization. A dollar valuation of their efforts is not reflected in the consolidated financial statements since it does not meet the criteria for recognition.

The President/CEO and certain other staff members of the Organization contribute office space to the Organization. As the value of the contributed rent could not be estimated, no amount for the contributed rent was recorded on the accompanying consolidated financial statements.

Fair value of financial instruments - Financial instruments primarily consist of investments, accounts receivable, and contributions and grants receivable. The Organization estimates that the fair value of its financial instruments at December 31, 2022 do not differ materially from its aggregate carrying value recorded in the accompanying statement of financial position. Considerable judgment is required in interpreting market data to develop the estimates of fair value and, accordingly, the estimates are not necessarily indicative of the amounts that the Organization could realize in a current market exchange.

Fair value measurements - The Organization defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The Organization measures fair value under a framework that provides a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (level 1 measurements), moderate priority to valuations based on observable inputs, such as market prices of similar assets and liabilities (level 2), and the lowest priority to unobservable inputs (level 3).

Cash and cash equivalents - For the purpose of reporting cash flows, cash and cash equivalents include operating cash held in banks. The Organization maintains its cash balances in several financial institutions, which at times may exceed federally insured limits. However, as part of its regular risk management strategies, the Organization assesses its holdings at least quarterly to ensure that all cash is held at financially stable and highly rated institutions, and assets are managed in ways to limit its risks and exposures.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS DECEMBER 31, 2022

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Continued

Investments - Investments in marketable securities are reported at fair value. Realized gains and losses (computed by the specific identification method) and unrealized gains and losses are included in the statement of activities. Interest and dividend income are recorded on the accrual basis of accounting.

Investments in equity, fixed income, certificates of deposit and debt securities with readily determinable market values are reported at fair value. The fair value of investments is valued at the closing price on the last business day of the fiscal year. Realized gains and losses are calculated based upon the underlying cost of the securities traded.

Investments are made according to the investment policies, guidelines and objectives adopted by the Board of Directors. These guidelines provide for investments in equities, fixed income and other securities with performance measured against appropriate indices. Market values of such investments and credit ratings of bond issues are routinely reviewed by the Board of Directors.

Contributions receivable - Contributions receivable represent contributions to the Organization by private donors that are collectible after the year-end. It is the policy of management to review outstanding contributions receivables at year end, as well as any historical bad debt write-offs, to establish an allowance for uncollectable amounts. Collection losses related to contributions receivable have historically been minimal. As such, no allowance for uncollectible accounts was recorded.

Grants payable - Grants payable as of December 31, 2022, were funds committed by the Organization to other entities for the advancement of research, medical education, and to increase awareness of ME/CFS and other multi-system chronic complex diseases.

Grant research - Grant research represents funds granted to clinical and academic research facilities for direct research into multi-system chronic complex diseases.

Foreign currency translation - The U.S. Dollar is the functional currency for the Organization. Transactions in currencies other than U.S. Dollars are translated into dollars at the approximate rates of exchange in effect during the time of the transaction.

Current assets, current liabilities and net assets with donor restrictions denominated in non-U.S. currency are translated into dollars at the exchange rate in effect at the date of the Statements of Financial Position.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS DECEMBER 31, 2022

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Continued

Currency gains and losses from translation are recorded as an Other Item in the accompanying Statement of Activities.

Expense allocation - The costs of providing various programs and other activities have been summarized on a functional basis in the statement of activities and in the statement of functional expenses. During the year, costs are categorized into separate groupings as either direct or indirect. Indirect or shared costs are allocated among program and support activities by the method that best measures the relative degree of benefit.

Program services - Expenses include costs that primarily relate to research projects and other costs supporting medical research.

Supporting services - Expenses include costs that primarily relate to management and general administration

Fundraising - Expenses include costs that primarily relate to fundraising activities to obtain grants and generate revenue through contributions.

Income taxes - The Foundation is a qualified non-profit organization under Section 501(c) (3) of the Internal Revenue Code ("IRC") and is not classified as a private foundation. Non-profit organizations are not generally liable for taxes on income; therefore, no provision is made for such taxes for the Organization in the consolidated financial statements. The Organization had no unrelated business income during the years ended December 31, 2022.

The Canadian Corporation is exempt from income tax as a registered charity under the Income Tax Act of Canada.

The Australian Limited Entity is also exempt from income tax as a Charity registered with the Australian Charities and Not-for-Profit Commission and endorsed by the Australian Taxation Office for charity tax concessions under Income Tax Act of 1997 of Australia.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS DECEMBER 31, 2022

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Continued

The Organization recognizes the impact of tax positions in the consolidated financial statements if that position is more likely than not of being sustained in an audit, based on the technical merits of the position. To date, the Organization has not recorded any uncertain tax positions. During the year ended December 31, 2022, the Organization did not recognize any amount in potential interest and penalties associated with uncertain tax positions. As of December 31, 2022, all federal tax returns since the 2019 tax year and state tax returns since the 2018 tax year of Foundation, the Canadian Corporation from 2018, and the Australian Limited Entity from 2019 are still subject to adjustment upon audit. No tax returns are currently being examined by taxing authorities.

Risks and uncertainties - Certain services of the Organization are governed by grant agreements with foundations. Failure to fulfill grant terms could result in the return of funds to grantors. Although it is a possibility, the Organization considers the contingency remote since, by accepting the grant and its terms, the Organization acknowledges the requirements of the grantor at the time of award.

Comparative totals - The consolidated financial statements include certain prior year summarized comparative information in total, but not by net asset class. The notes to the consolidated financial statements do not contain the financial information on a comparative basis. Such summarized information does not include sufficient detail to constitute a presentation in conformity with accounting principles generally accepted in the United States of America. Accordingly, such information should be read in conjunction with the Organization's financial statements for the year ended December 31, 2021, from which the summarized information was derived.

Reclassifications - Certain amounts previously presented in previous financial statements have been reclassified to conform to the current presentation of the accompanying consolidated financial statements to maintain consistency between reporting periods presented.

Subsequent events - Subsequent events have been evaluated by the Organization through April 18, 2023, which is the date these consolidated financial statements were able to be issued, and no subsequent events have arisen that would require disclosure.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS DECEMBER 31, 2022

NOTE 3 - NET ASSETS WITH DONOR RESTRICTIONS

Net assets with donor restrictions, net of foreign currency transaction gain, for the following purposes or periods at December 31, 2022 consist of the following:

| | January 1, 2022 | Additions | Releases | December 31, 2022 |
|--|--------------------|-----------|-------------|----------------------|
| With Donor Restrictions - OMF | | | | |
| General Research Funds | | | | |
| General Research Programs | \$- | \$ 2,050 | \$ - | \$ 2,050 |
| ME/CFS Research | 378,112 | 177,374 | (535,957) | 19,529 |
| Covid-19 Research | 398,586 | 316 | (398,902) | - |
| Lyme Research | 65,294 | 650 | (65,394) | 550 |
| Harvard Collaborative Research Center | | | | |
| Harvard CRC General Funds | 300,987 | 42,169 | (329,256) | 13,900 |
| PEM Muscle Biopsy | - | 831 | - | 831 |
| Network Analysis | - | 207,288 | - | 207,288 |
| PASS/CAT, Kalman Filters | 19,823 | - | (19,823) | - |
| Melbourne Collaborative Research Center | | | | |
| Melbourne CRC General Funds | - | 7,182 | - | 7,182 |
| Nitrogen Metabolism Studies | 361,625 | - | - | 361,625 |
| Montreal Collaborative Research Center | | | | |
| Montreal CRC General Funds | 10,950 | - | (10,950) | - |
| Multi-Omics/MOSAICS | - | 1,059,458 | - | 1,059,458 |
| Stanford Collaborative Research Center | | | | |
| Stanford CRC General Funds | 434,015 | 57,082 | (39,662) | 451,435 |
| Diagnostic Technologies - Nanoneedle | 2,873 | - | - | 2,873 |
| Stanford Centrifuge | 15,727 | - | (15,727) | - |
| Stanford Family Study | 54,605 | - | - | 54,605 |
| Stanford Flourescent Microscope Project | 43,427 | - | (43,427) | - |
| Stanford Metabolic Trap | 82 | 538 | - | 620 |
| Whitney Dafoe | - | 44,005 | - | 44,005 |
| Laurel Crosby's BH4 Deficiency in Long COVID | - | 333,420 | (333,420) | - |
| Uppsala Collaborative Research Center | | | | |
| Upppsala CRC General Funds | 129,426 | 62,188 | - | 191,614 |
| Other Programs | | | | |
| Clinical Coalition & Symposiums | 200,936 | - | (48,325) | 152,611 |
| Fundraising Operations | 147,500 | - | (147,500) | - |
| Physician/Medical Education | 53,549 | 14,500 | (4,800) | 63,249 |
| Bateman Horne Center Medical Education | - | 578 | - | 578 |
| CROMOLYN & IBUPROFEN study | - | 80,000 | - | 80,000 |
| Microbial Metabolites | | 65,702 | | 65,702 |
| | 2,617,517 | 2,155,331 | (1,993,143) | 2,779,705 |

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS DECEMBER 31, 2022

NOTE 3 - NET ASSETS WITH DONOR RESTRICTIONS, Continued

| | January 1, 2022 | Additions | Transfers | Releases | December 31, 2022 |
|---|--------------------|-------------|-------------|----------------------|----------------------|
| With Donor Restrictions - OMF CANADA | | | | | |
| General Research Funds - Canada | _ | | | | |
| ME/CFS Research | 2,889 | 133 | - | - | 3,022 |
| Clinical Trials | - | 100,366 | - | - | 100,366 |
| Harvard Collaborative Research Center - Canada | _ | | | | |
| Harvard CRC General Funds | 248 | 193 | - | - | 441 |
| Microglial Activation | 531,626 | 37,261 | (568,887) | - | - |
| iCPET Multi-Omic | 163,401 | - | (114,153) | - | 49,248 |
| Montreal Collaborative Research Center- Canada | _ | | | | |
| Montreal CRC General Funds | 1,166 | 294 | - | - | 1,460 |
| REMEDIAL | 239,415 | 710,867 | - | (710,789) | 239,493 |
| DOMINO-ME | 103,886 | - | - | (103,886) | - |
| RASPBERRY-ME | | - | 114,153 | (114,153) | - |
| Fibromyalgia Research | - | 88 | - | - | 88 |
| Stanford Collaborative Research Center - Canada | - | | | | |
| Stanford CRC General Funds | 3,911 | 1,138 | - | - | 5,049 |
| Uppsala Collaborative Research Center - Canada | _ | | | | |
| Deep Assessment of Neuroinflammation | | | 568,887 | | 568,887 |
| | 1,046,542 | 850,340 | | (928,828) | 968,054 |
| Total Net Assets With Donor Restrictions | \$3,664,059 | \$3,005,671 | <u>\$ -</u> | <u>\$(2,921,971)</u> | <u>\$ 3,747,759</u> |

NOTE 4 - INVESTMENTS

The following is a description of the valuation methodologies used for the investments measured at fair value, including the general classification of such instruments pursuant to the valuation hierarchy. All investments held at December 31, 2022 and during the fiscal year are classified as level 1 under the valuation hierarchy.

Certificates of deposit - Certificates of deposit (CDs) are a time deposit. CDs are similar to savings accounts in that they are insured. All CDs have maturities of one to two years from their origination dates with interest rates ranging from 3.15% to 4.80%.

U.S. government securities - U.S. government securities, including US Treasury Bills, are valued at the closing price reported in the active market in which the individual security is traded.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS DECEMBER 31, 2022

NOTE 4 – INVESTMENTS, Continued

Money market funds - Money market funds are open-ended mutual funds that invest in shortterm debt securities such as U.S. Treasury bills and commercial paper. The fair values of the money market funds were obtained based on quoted market prices at the closing of the last business day of the fiscal year.

The preceding methods described may produce a fair value calculation that may not be indicative of net realizable value or reflective of future values. Furthermore, although the Organization believes its valuation methods are appropriate and consistent with other market participants, the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different fair value measurement at the reporting date.

The following table provides the fair value for each major category of assets measured at fair value at December 31, 2022:

| Money market funds | \$ | 5,500 |
|-----------------------------|------|---------|
| Certificates of deposit | | 352,609 |
| U. S. government securities | 1, | 134,141 |
| | \$1, | 492,250 |

NOTE 5 – EMPLOYEE BENEFIT PLAN

The Organization provides a 403(b) retirement savings plan (the "Plan"), which covers all eligible employees of the Organization. Participants may defer up to the maximum annual contributions under applicable tax regulations. During the year ended, December 31, 2022, the Organization did not make any matching or discretionary contributions to the Plan.

SUPPLEMENTARY SCHEDULES

(A NON-PROFIT CORPORATION)

CONSOLIDATING SCHEDULE OF FINANCIAL POSITION DECEMBER 31, 2022

| | | | OMF | | OMF | | | | | | |
|---------------------------------------|-----------------|----|-----------|----|-----------|----|------------|----|----------|--------------|--|
| | OMF | | Canada | A | Australia | | Total | | inations | Consolidated | |
| ASSETS | | | | | | | | | | | |
| CURRENT ASSETS | | | | | | | | | | | |
| Cash and cash equivalents | \$ 5,859,973 | \$ | 1,358,757 | \$ | 464,433 | \$ | 7,683,163 | \$ | - | \$ 7,683,163 | |
| Investments | 1,492,250 | | - | | - | | 1,492,250 | | - | 1,492,250 | |
| Contributions receivable | 1,332,448 | | - | | 18 | | 1,332,466 | | - | 1,332,466 | |
| Other receivables | - | | 2,591 | | - | | 2,591 | | - | 2,591 | |
| | \$ 8,684,671 | \$ | 1,361,348 | \$ | 464,451 | \$ | 10,510,470 | \$ | - | \$10,510,470 | |
| LIABILITIES AND NET ASSETS | | | | | | | | | | | |
| CURRENT LIABILITIES | | | | | | | | | | | |
| Accounts payable and accrued expenses | \$ 31,101 | \$ | 7,993 | \$ | 6,779 | \$ | 45,873 | \$ | - | \$ 45,873 | |
| Grants payable | 3,778,697 | | - | | | | 3,778,697 | | - | 3,778,697 | |
| | 3,809,798 | | 7,993 | | 6,779 | | 3,824,570 | | - | 3,824,570 | |
| NET ASSETS | | | | | | | | | | | |
| Without donor restrictions | 2,095,168 | | 385,301 | | 457,672 | | 2,938,141 | | - | 2,938,141 | |
| With donor restrictions | 2,779,705 | | 968,054 | | - | | 3,747,759 | | - | 3,747,759 | |
| | 4,874,873 | | 1,353,355 | | 457,672 | | 6,685,900 | | - | 6,685,900 | |
| | \$ 8,684,671 | \$ | 1,361,348 | \$ | 464,451 | \$ | 10,510,470 | \$ | - | \$10,510,470 | |

(A NON-PROFIT CORPORATION)

CONSOLIDATING SCHEDULE OF ACTIVITIES DECEMBER 31, 2022

| | | OMF | | | OMF Canada | | (| OMF Australi | a | | |
|---------------------------------------|---------------------|--------------|--------------------|---------------------|-------------------|--------------------|---------------------|--------------|-------------------|---------------------|--------------|
| | Without | With | | Without | With | | Without | With | | | |
| | Donor | Donor | | Donor | Donor | | Donor | Donor | | | Grand |
| | Restrictions | Restrictions | <u>Total</u> | Restrictions | Restrictions | <u>Total</u> | Restrictions | Restrictions | <u>Total</u> | <u>Eliminations</u> | <u>Total</u> |
| REVENUE AND SUPPORT | | | | | | | | | | | |
| Contributions | \$1,410,870 | \$ 389,222 | \$1,800,092 | \$ 239,116 | \$ 2,498 | \$ 241,614 | \$ 140,154 | \$ - | \$ 140,154 | \$ - | \$ 2,181,860 |
| Grants | 419,727 | 1,766,109 | 2,185,836 | 1,986 | 847,842 | 849,828 | - | - | - | - | 3,035,664 |
| Other income | 7,568 | - | 7,568 | 1,115 | - | 1,115 | - | - | - | (7,008) | 1,675 |
| Interest income | 12,828 | - | 12,828 | 6,440 | - | 6,440 | - | - | - | - | 19,268 |
| Loss on investments | (18,514) | - | (18,514) | - | - | - | - | - | - | - | (18,514) |
| Net assets released from restrictions | 1,993,143 | (1,993,143) | - | 928,828 | (928,828) | - | - | - | - | - | - |
| | 3,825,622 | 162,188 | 3,987,810 | 1,177,485 | (78,488) | 1,098,997 | 140,154 | - | 140,154 | (7,008) | 5,219,953 |
| EXPENSES | | | | | | | | | | | |
| Program services | 6,081,763 | - | 6,081,763 | 1,136,052 | - | 1,136,052 | 7,008 | - | 7,008 | (7,008) | 7,217,815 |
| Supporting services | 292,673 | - | 292,673 | 3,854 | - | 3,854 | - | - | - | - | 296,527 |
| Fundraising | 462,406 | - | 462,406 | 2,621 | | 2,621 | 931 | | 931 | | 465,958 |
| | 6,836,842 | - | 6,836,842 | 1,142,527 | - | 1,142,527 | 7,939 | - | 7,939 | (7,008) | 7,980,300 |
| OTHER ITEMS | | | | | | | | | | | · |
| Foreign currency translation loss | | | | (101,105) | | (101,105) | (26,586) | | (26,586) | | (127,691) |
| CHANGE IN NET ASSETS | (3,011,220) | 162,188 | (2,849,032) | (66,147) | (78,488) | (144,635) | 105,629 | - | 105,629 | - | (2,888,038) |
| NET ASSETS, beginning of year | 5,106,388 | 2,617,517 | 7,723,905 | 451,448 | 1,046,542 | 1,497,990 | 352,043 | | 352,043 | | 9,573,938 |
| NET ASSETS, end of year | \$2,095,168 | \$2,779,705 | <u>\$4,874,873</u> | \$ 385,301 | <u>\$ 968,054</u> | <u>\$1,353,355</u> | \$ 457,672 | <u>\$</u> | <u>\$ 457,672</u> | <u>\$ -</u> | \$ 6,685,900 |

(A NON-PROFIT CORPORATION)

CONSOLIDATING SCHEDULE OF FUNCTIONAL EXPENSES DECEMBER 31, 2022

| | | 0 | MF | | | OMF | Canada | | OMF Australia | | | _ | | |
|-----------------------------------|---------------------|------------------------|-------------|-------------|---------------------|------------------------|-------------|-------------|---------------------|-------------|-------------|----------|--------------------|----------------|
| | Program Services | Supporting Services | Fundraising | Total | Program Services | Supporting Services | Fundraising | Total | Program Services | | Fundraising | Total | Eliminations | Grand Total |
| Salaries and wages | \$ 362,799 | \$ 155,528 | \$ 313,829 | \$ 832,156 | \$ - | \$ - | \$ - | \$ - | \$ - | \$ - | \$- | \$ - | \$ - | \$ 832,156 |
| Payroll taxes | 22,244 | 9,535 | 19,242 | 51,021 | - | - | - | - | - | - | - | - | - | 51,021 |
| Employee benefits | 12,121 | 5,196 | 10,485 | 27,802 | - | - | - | - | - | - | - | - | - | 27,802 |
| Total personnel expenses | 397,164 | 170,259 | 343,556 | 910,979 | - | - | - | - | - | - | - | - | - | 910,979 |
| Program and research grants | 5,450,094 | - | - | 5,450,094 | 1,121,269 | - | - | 1,121,269 | - | - | - | - | - | 6,571,363 |
| Professionals services | 170,948 | 43,575 | 2,742 | 217,265 | 14,783 | - | - | 14,783 | - | - | - | - | - | 232,048 |
| Information technology | 15,736 | 10,721 | 25,700 | 52,157 | - | - | - | - | - | - | - | - | - | 52,157 |
| Merchant fees | - | - | 61,526 | 61,526 | - | - | 2,621 | 2,621 | - | - | 931 | 931 | - | 65,078 |
| Contract service expenses paid to | | | | | | | | | | | | | | |
| OMF Foundation by OMF AUS | - | - | - | - | - | - | - | - | 7,008 | - | - | 7,008 | (7,008) | - |
| Fundraising | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Marketing and | | | | | | | | | | | | | | |
| communications | 28,883 | - | 28,882 | 57,765 | - | - | - | - | - | - | - | - | - | 57,765 |
| Insurance | - | 11,347 | - | 11,347 | - | - | - | - | - | - | - | - | - | 11,347 |
| Travel, meetings and | | | | | | | | | | | | | | |
| conferences | - | 48,420 | - | 48,420 | - | - | - | - | - | - | - | - | - | 48,420 |
| General administration | - | 7,726 | - | 7,726 | - | 3,854 | - | 3,854 | - | - | - | - | - | 11,580 |
| Website | 18,938 | - | - | 18,938 | - | - | - | - | - | - | - | - | - | 18,938 |
| Taxes and licenses | | 625 | - | 625 | - | | | - | | | - | | | 625 |
| | \$6,081,763 | \$ 292,673 | \$ 462,406 | \$6,836,842 | \$1,136,052 | \$ 3,854 | \$ 2,621 | \$1,142,527 | \$ 7,008 | <u>\$</u> - | \$ 931 | \$ 7,939 | <u>\$ (7,008</u>) | \$7,980,300 |